Bio-Techne Appoints Nobel Laureate Dr. Yamanaka to Board
Ticker: TECH · Form: 8-K · Filed: Apr 30, 2024 · CIK: 842023
| Field | Detail |
|---|---|
| Company | Bio-Techne Corp (TECH) |
| Form Type | 8-K |
| Filed Date | Apr 30, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-appointment, governance, biotech
TL;DR
Nobel winner Yamanaka joins Bio-Techne board, big for stem cell tech.
AI Summary
Bio-Techne Corporation announced on April 24, 2024, the appointment of Dr. H. Shinya Yamanaka to its Board of Directors. Dr. Yamanaka, a Nobel Prize laureate, brings extensive expertise in stem cell research and regenerative medicine. His appointment is expected to enhance Bio-Techne's strategic direction in these critical areas.
Why It Matters
The addition of a renowned scientist like Dr. Yamanaka could significantly bolster Bio-Techne's research and development capabilities, potentially leading to breakthroughs in regenerative medicine and advanced therapies.
Risk Assessment
Risk Level: low — The appointment of a director is a standard corporate governance event with no immediate financial risk.
Key Players & Entities
- Bio-Techne Corporation (company) — Registrant
- Dr. H. Shinya Yamanaka (person) — Newly appointed Director
- April 24, 2024 (date) — Date of earliest event reported
FAQ
Who is Dr. H. Shinya Yamanaka?
Dr. H. Shinya Yamanaka is a Nobel Prize laureate known for his work in stem cell research and regenerative medicine, and has been appointed to Bio-Techne's Board of Directors.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on April 24, 2024.
What is Bio-Techne Corporation's principal executive office address?
Bio-Techne Corporation's principal executive offices are located at 614 McKinley Place NE, Minneapolis, Minnesota 55413.
What is Bio-Techne's fiscal year end?
Bio-Techne's fiscal year ends on June 30.
What is the SIC code for Bio-Techne Corporation?
The Standard Industrial Classification (SIC) code for Bio-Techne Corporation is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 662 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-04-30 16:30:14
Filing Documents
- tmb-20240424x8k.htm (8-K) — 43KB
- tmb-20240424xex99d1.htm (EX-99.1) — 5KB
- 0001558370-24-006279.txt ( ) — 166KB
- tmb-20240424.xsd (EX-101.SCH) — 3KB
- tmb-20240424_lab.xml (EX-101.LAB) — 15KB
- tmb-20240424_pre.xml (EX-101.PRE) — 11KB
- tmb-20240424x8k_htm.xml (XML) — 5KB
01 Other Events
Item 8.01 Other Events A copy of the press release issued by Bio-Techne Corporation on April 30, 2024, announcing Dr. Klimovsky's appointment is attached hereto as Exhibit 99.1.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release, dated April 30, 2024, announcing appointment of Dr. Klimovsky as director 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIO-TECHNE CORPORATION Date: April 30, 2024 By: /s/ Shane V. Bohnen Shane V. Bohnen Senior Vice President, General Counsel and Corporate Secretary